Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact

If envudeucitinib is approved, it will join a competitive oral psoriasis market flanked by drugs Icotyde, Otezla and Sotyktu. If envudeucitinib gains approval, it will join an increasingly competitive market flanked by drugs like J&J’s Icotyde, Amgen’s Otezla and BMS’ Sotyktu. Alumis is on track to submit a new drug application for envudeucitinib in plaque psoriasis in Q4 2026. Credit: Nadiia Lapshynska / Shutterstock.com. California-based biopharma company Alumis has debuted data from a trio of Phase III studies that the company says highlights the “leading” potential of its tyrosine kinase 2 (TYK2) inhibitor, envudeucitinib, on the oral psoriasis market. These…

Source: Clinical Trials Arena